DENVER, Colo. (247marketnews.com) -- Creative Medical (NASDAQ:CELZ) is continuing to attract investor attention after building on yesterday's patent-driven rally, with shares reaching an intraday high of $1.94 as momentum carried into a second trading session. The latest move follows news that the U.S. Patent and Trademark Office issued a Notice of Allowance for a new patent covering the company's exosome-based immunotherapy platform targeting Type 1 diabetes, further strengthening its growing intellectual property portfolio.
The newly allowed patent protects Creative Medical's MyeloCelz™ technology, a cell-free exosome platform designed to suppress the autoimmune destruction of insulin-producing pancreatic beta cells. Unlike therapies focused primarily on insulin replacement or glucose management, the platform is designed to induce antigen-specific immune tolerance while preserving normal immune function. The patent also covers use of the exosomes alongside antibodies, cellular therapies, and small molecules, potentially broadening future development and commercialization opportunities.
The allowance further reinforces what has become a diversified diabetes pipeline. Creative Medical is advancing CELZ-201 (AlloStem®) in the FDA-cleared CREATE-1 clinical trial for newly diagnosed Type 1 diabetes, while CELZ-101 (ImmCelz®) has received FDA Orphan Drug Designation for use with pancreatic islet transplantation in brittle Type 1 diabetes. Together with MyeloCelz™ and its Type 2 diabetes program, the company is pursuing multiple approaches designed to modify disease progression rather than simply manage symptoms.
Beyond the scientific developments, the expanding patent estate may strengthen Creative Medical's long-term strategic position. The company now reports approximately 60 issued patents and pending applications, with plans to continue expanding protection around its regenerative medicine and immunology platforms while advancing ongoing clinical studies and evaluating potential licensing and partnership opportunities.
From a trading perspective, today's move has placed CELZ firmly back on momentum traders' watchlists. After breaking above the previously identified $1.44 trigger level, shares extended to $1.94, a level that may attract additional technical interest. While market participants will ultimately determine future price direction, some traders may note that historical trading activity suggests relatively limited overhead resistance in the immediate area compared with prior consolidation levels. Support is now being watched near $1.44, with additional support around $1.22.
With approximately 2.1 million Americans living with Type 1 diabetes and no approved cure currently available, investor focus is likely to remain on companies pursuing disease-modifying therapies with meaningful intellectual property protection. As Creative Medical continues advancing its clinical programs while expanding its patent portfolio, CELZ could remain a closely watched biotechnology name for both fundamental and momentum investors.
Sources
Creative Medical Technology Holdings: https://creativemedicaltechnology.com/
U.S. Patent and Trademark Office (USPTO): https://www.uspto.gov/
U.S. Centers for Disease Control and Prevention – Type 1 Diabetes: https://www.cdc.gov/diabetes/
SEC Filings – Creative Medical (NASDAQ: CELZ): https://www.sec.gov/edgar/search/
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.